Jazz Pharmaceuticals, Inc.
United States
510 articles about Jazz Pharmaceuticals, Inc.
-
The FDA has upheld the accelerated approval of Jazz Pharmaceuticals’ Zepzelca (lurbinectedin), even though the drug failed to reach its primary endpoint in the confirmatory Phase III ATLANTIS trial.
-
Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022
10/26/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third quarter financial results on Wednesday, November 9, 2022, after the close of the U.S. financial markets.
-
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
10/19/2022
Zymeworks Inc. announced that management will host a conference call and webcast to discuss Zymeworks has entered into an exclusive licensing agreement for zanidatamab, a HER2-targeted bispecific antibody developed using Zymeworks’ proprietary Azymetric™ platform, with Jazz Pharmaceuticals plc.
-
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
10/19/2022
Jazz Pharmaceuticals plc and Zymeworks Inc. announced that Jazz and Zymeworks' subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks' zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.
-
Jazz and Zymeworks entered into a $50 million licensing agreement over zanidatamab, Zymeworks’ bispecific antibody targeting HER2.
-
Colossal started the “de-extinction” of the thylacine, commonly known as the Tasmania tiger. Now with a $30 million investment, this technology is gaining more traction.
-
Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
9/15/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present seven abstracts from across its neuroscience portfolio at the 35th annual Psych Congress 2022, being held September 17-20, 2022.
-
Jazz Pharmaceuticals to Participate in Upcoming September 2022 Investor Conferences
8/31/2022
Jazz Pharmaceuticals plc announced that the company will participate in the following upcoming investor conferences.
-
Jazz Pharma is breaking new ground with its cannabidiol epilepsy treatment Epidiolex, taking the drug into a Phase III study in children and adolescents.
-
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
8/18/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex® (cannabidiol), known as Epidyolex® in Europe, in children and adolescents with Epilepsy with Myoclonic-Atonic Seizures (EMAS).
-
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
8/3/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance and provided business updates.
-
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
7/20/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 second quarter financial results on Wednesday, August 3, 2022, after the close of the U.S. financial markets.
-
Avadel and Jazz Pharma, a leader in treating sleep disorders, are locked in a patent dispute. If it receives final FDA approval, Avadel's Lumryz could challenge Jazz's market dominance.
-
Otsuka and Lunbeck report positive Phase III results in agitation in Alzheimer's, Acer's vEDS program hits Phase III and BridgeBio's primary hyperoxaluria type 1 program progresses.
-
The Phase III study of Jazz Pharmaceuticals cannabis-derived MS Sativex failed to achieve the primary endpoint of an improvement in muscle tone in patients.
-
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
6/28/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 RELEASE MSS1 trial ( NCT04657666 ) evaluating nabiximols oromucosal spray (JZP378, or Sativex ® , ex-U.S.) on clinical measures of spasticity in individuals with multiple sclerosis (MS).
-
Jazz Pharmaceuticals, Redx Pharma and Omega Therapeutics are pushing forward with their cancer treatments with Investigational New Drug approval and IND application submission.
-
It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.
-
Greg Grunberg, who has appeared in multiple Star Wars projects, has partnered with Jazz Pharmaceuticals to bring "The Care Giver", a video web series, to life.
-
CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.